A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

In those with and those without emphysema, patients receiving dupilumab vs. placebo had a lower annualized exacerbation rate. Both groups also had improved lung function with dupilumab vs.

Dupilumab use in asthma is linked to higher lymphoma risk, especially T and NK cell types, but also shows reduced all-cause ...

Treating atopic dermatitis (AD) with dupilumab vs other systemic agents increased the risk of developing psoriasis over 3 years, a cohort study found. Addressing postmarketing reports of psoriasis ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced. In the study, 106 patients were randomized to 300 mg of subcutaneous ...